Hookipa Biotech AG has signed a licencing deal with Gilead Sciences Inc giving the US company exclusive rights to its technology platform to develop vaccines targeting the hepatitis B and the human immunodeficiency viruses. The agreement brings Austria-based Hookipa into a closer alliance with Gilead which invested an undisclosed amount of money in Hookipa’s €50 million Series C investment round in December 2017.
